Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuronetics (STIM) EBT (2017 - 2025)

Historic EBT for Neuronetics (STIM) over the last 9 years, with Q3 2025 value amounting to -$9.5 million.

  • Neuronetics' EBT fell 78.28% to -$9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.7 million, marking a year-over-year decrease of 3102.25%. This contributed to the annual value of -$41.8 million for FY2024, which is 1631.83% down from last year.
  • Neuronetics' EBT amounted to -$9.5 million in Q3 2025, which was down 78.28% from -$10.0 million recorded in Q2 2025.
  • Neuronetics' EBT's 5-year high stood at -$6.3 million during Q4 2023, with a 5-year trough of -$13.2 million in Q4 2024.
  • Over the past 5 years, Neuronetics' median EBT value was -$9.5 million (recorded in 2024), while the average stood at -$9.5 million.
  • Within the past 5 years, the most significant YoY rise in Neuronetics' EBT was 3360.25% (2021), while the steepest drop was 13861.65% (2021).
  • Neuronetics' EBT (Quarter) stood at -$8.0 million in 2021, then fell by 12.12% to -$8.9 million in 2022, then increased by 29.85% to -$6.3 million in 2023, then crashed by 110.96% to -$13.2 million in 2024, then rose by 27.98% to -$9.5 million in 2025.
  • Its EBT was -$9.5 million in Q3 2025, compared to -$10.0 million in Q2 2025 and -$12.9 million in Q1 2025.